Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 16:20 save search
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn328 congress cell trial therapeutics response
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Published: 2023-06-10 (Crawled : 16:20) - globenewswire.com
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
| Email alert
Add to watchlist
gc012 response results
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn217 therapeutics
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
| Email alert
Add to watchlist
t-cell presentation potential
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
| Email alert
Add to watchlist
meeting
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
meeting t-cell therapeutics therapy
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
Published: 2022-06-11 (Crawled : 16:20) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
| Email alert
Add to watchlist
ctx130 crispr trial therapeutics positive results phase 1
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
| Email alert
Add to watchlist
technology presentation biotech iot platform t-cell
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-11 (Crawled : 16:20) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
balli-01 ema leukemia preclinical t-cell pre-clinical
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
Published: 2021-04-10 (Crawled : 16:20) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
| Email alert
Add to watchlist
crispr car-t t-cell preclinical pre-clinical
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.